Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats.
Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL-4 and interferon-gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats.
Sáez-Torres
I
I
Unitat de Neuroimmunologia Clínica, Department of Neurology, Hospital General Vall d'Hebron, Universitat Autònoma de Barcelona, Universitat Politècnica de Catalunya, ETSEIB, Barcelona, Spain. isaez@hg.vhebron.es
Espejo
C
C
Pérez
J J
JJ
Acarín
N
N
Montalban
X
X
Martínez-Cáceres
E M
EM
D000818:Animals; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D005260:Female; D006168:Guinea Pigs; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D015717:Peptide T / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D051381:Rats; D011917:Rats, Inbred Lew
D015717:Peptide T; D015847:Interleukin-4; D007371:Interferon-gamma